ArticleNature communications2019
PD-1 blockade potentiates HIV latency reversal ex vivo in CD4
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 2 pooled it
14.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 2 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.Viruses · 2022Pooled it
- Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.The Journal of infectious diseases · 2026Trial
- Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade.AIDS research and human retroviruses · 2021Trial
- Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.JAMA oncology · 2020Trial
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Review
- TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size.Nature immunology · 2026Article
- Network Pharmacology-Guided Identification ofInternational journal of molecular sciences · 2026Article
- Neuroinflammation and NeuroHIV: understanding the role of HIV-1 related factors in microglial activation.Translational psychiatry · 2026Review
- A novel antiviral strategy by disrupting the equilibrium of virus-host calcium homeostasis.Current opinion in virology · 2026Review
- Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.Nature medicine · 2026Article
- Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
- Effective and safe use of immune checkpoint inhibitors for non-small cell lung cancer in people living with HIV.HIV medicine · 2025Review
- Age-Associated Expansion of HIV/SIV Reservoirs in People With HIV and SIV-Infected Macaques.Aging cell · 2025Article
- Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025Review
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 4 countries.
Rémi FromentinCentre de Recherche du CHUM, Montréal, H2X0A9, QC, Canada.
Sandrina DaFonsecaCaprion Biosciences Inc., Montréal, H2X3Y7, QC, Canada.
Cecilia T CostiniukChronic Viral Illness Service and Division of Hematology, Research Institute, McGill University Health Centre, Montréal, H4A3J1, QC, Canada.
Mohamed El-FarCentre de Recherche du CHUM, Montréal, H2X0A9, QC, Canada.
Francesco Andrea ProcopioService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011, Lausanne, Switzerland.
Frederick M HechtDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94115, USA.ORCID http://orcid.org/0000-0002-5782-1171
Rebecca HohDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94115, USA.
Steven G DeeksDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94115, USA.ORCID http://orcid.org/0000-0001-6371-747X
Daria J HazudaInfectious Disease, Merck Research Laboratories, West Point, PA, 19486, USA.
Sharon R LewinThe Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, 3000, Australia.
Jean-Pierre RoutyChronic Viral Illness Service and Division of Hematology, Research Institute, McGill University Health Centre, Montréal, H4A3J1, QC, Canada.ORCID http://orcid.org/0000-0001-9897-7589
Rafick-Pierre SékalyCase Western Reserve University, Cleveland, OH, 44106, USA.
Nicolas ChomontCentre de Recherche du CHUM, Montréal, H2X0A9, QC, Canada. nicolas.chomont@umontreal.ca.ORCID http://orcid.org/0000-0001-9747-5018
Centre Hospitalier de l’Université de Montréal · CAUniversity of California, San Francisco · USMcGill University Health Centre · CACaprion (Canada) · CACase Western Reserve University · USThe Royal Melbourne Hospital · AUUnited States Military Academy · USUniversity of Lausanne · CH
Funding
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PALMER, SARAH ELIZABETH · 2011 to 2015
$29.5MDelaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MTILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoirR21AI113096 · NIAID · VGTI FLORIDA · PI CHOMONT, NICOLAS · 2014 to 2015
$334kNIAID NIH HHS P30 AI027763NIAID NIH HHS R21 AI113096NIAID NIH HHS R24 AI067039NIAID NIH HHS U19 AI096109NIAID NIH HHS UM1 AI126611
Abstract
HIV persists in latently infected CD4
Indexed as
Antiretroviral Therapy, Highly ActiveAntibodies, Monoclonal, HumanizedB7-H1 AntigenBryostatinsCD4-Positive T-LymphocytesHIV-1HumansLymphocyte ActivationProgrammed Cell Death 1 ReceptorVirus LatencyAntibodies, Monoclonal, HumanizedB7-H1 AntigenBryostatinsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.